alexa Exposure to a Mycobacterial Antigen, ESAT-6, Exacerbates Granulomatous and Fibrotic Changes in a Multiwall Carbon Nanotube Model of Chronic Pulmonary Disease
ISSN: 2157-7439
Journal of Nanomedicine & Nanotechnology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Exposure to a Mycobacterial Antigen, ESAT-6, Exacerbates Granulomatous and Fibrotic Changes in a Multiwall Carbon Nanotube Model of Chronic Pulmonary Disease

Anagha Malur1, Barbara P Barna1, Janki Patel1, Matthew McPeek1, Christopher J Wingard2, Larry Dobbs3 and Mary Jane Thomassen1*

1Program in Lung Cell Biology and Translational Research, Division of Pulmonary, Critical Care and Sleep Medicine, East Carolina University, Greenville, NC, USA

2Department of Physiology, East Carolina University, Greenville, NC, USA

3Department of Pathology, East Carolina University, Greenville, NC, USA

*Corresponding Author:
Mary Jane Thomassen
Program in Lung Cell Biology and
Translational Research Division of Pulmonary
and Critical Care Medicine
East Carolina University
3E-149 Brody Medical Sciences Building
Greenville, NC 27834, USA
Tel: 1-252-744-1117
E-mail: [email protected]

Received Date: December 09, 2015; Accepted Date: December 17, 2015; Published Date: December 27, 2015

Citation: Malur A, Barna BP, Patel J, McPeek M, Wingard CJ, et al. (2015) Exposure to a Mycobacterial Antigen, ESAT-6, Exacerbates Granulomatous and Fibrotic Changes in a Multiwall Carbon Nanotube Model of Chronic Pulmonary Disease. J Nanomed Nanotechnol 6:340. doi:10.4172/2157-7439.1000340

Copyright: © 2015 Malur A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nanomedicine & Nanotechnology


Recent studies suggest additive effects of environmental pollutants and microbial antigens on respiratory disease. We established a granuloma model in which instilled multiwall carbon nanotubes (MWCNT) elicit granulomatous pathology. We hypothesized that mycobacterial antigen ESAT-6, a T cell activator associated with tuberculosis and sarcoidosis, might alter pathology. Wild-type C57Bl/6 mice received MWCNT with or without ESAT-6 peptide. Controls received vehicle (surfactant-PBS) or ESAT-6 alone. Mice were evaluated 60 days later for granulomas, fibrosis, and bronchoalveolar lavage (BAL) cell expression of inflammatory mediators (CCL2, MMP-12, and Osteopontin). Results indicated increased granulomas, fibrosis, and inflammatory mediators in mice receiving the combination of MWCNT+ESAT-6 compared to MWCNT or vehicle alone. ESAT-6 alone showed no significant effect on these pathological endpoints. However, CD3 (+) lymphocyte infiltration of lung tissue increased with MWCNT+ESAT-6 versus MWCNT alone. Findings suggest that concurrent exposure to microbial antigen and MWCNT exacerbates chronic pulmonary disease.


Granuloma; Carbon nanotube; Mycobacterial antigen; Fibrosis


Carbon-based nanomaterials are naturally present within our environment but also constitute an important segment of industrially manufactured consumer products [1-4]. Within the environment, the importance and impact of carbon particles might be underestimated as causative agents and/or factors involved in the development of respiratory diseases. Experimental animals exposed to carbon nanotubes show persistence of nanotubes in vivo and in some cases, develop pulmonary granuloma-like lesions [5-7]. In other cases, carbon nanotubes may elicit other fibrotic changes [8,9].

In order to explore pathophysiologic mechanisms of granuloma formation and persistence, we developed a novel multiwall carbon nanotube (MWCNT) model of granulomatous disease [10]. MWCNTelicited granulomatous disease is chronic (where granulomas persist up to 90 days), and is characterized by persistently elevated pro-inflammatory cytokines together with T cell and macrophage recruitment – all traits found in sarcoidosis, a human granulomatous disease of unknown etiology [11]. Epidemiologic studies have linked sarcoidosis to some environmental risk factors that favor carbon nanotube formation in ambient air. Examples include exposure to wood-burning stoves, fireplaces, or firefighting [12-15].

Other reports have led to the possibility that mycobacterial products may also play a role in sarcoidosis [16]. Studies in sarcoidosis patients have detected T cell reactivity to peptide components of Early Secreted Antigenic Target Protein 6 (ESAT-6), a Mycobacterium tuberculosis secreted protein [17,18]. Production of interferon gamma (IFN-γ) by peripheral blood cells in response to ESAT-6 together with other peptide components of M. tuberculosis also forms the basis of clinical tests for detection of latent tuberculosis infection [19,20]. Administration of an ESAT-6 fusion protein has been shown to protect against M. tuberculosis infection in mice [21] but the possible effects of ESAT-6 exposure in association with a non-infectious, environmental pulmonary challenge such as MWCNT has not been explored. We hypothesized that concurrent administration of ESAT-6 with MWCNT might exacerbate MWCNT-mediated granulomatous disease.

Materials and methods

MWCNT model

All studies were conducted in conformity with Public Health Service (PHS) Policy on humane care and use of laboratory animals and were approved by the institutional animal care committee. C57BL/6J wild-type mice received an oropharyngeal instillation of MWCNT after sedation with isofluorane. MWCNTs (catalogue number 900–1501, lot GS1801, SES Research, Houston, TX) were freshly prepared and have been extensively described previously [21,22]. A single pulmonary instillation of MWCNT (100 μg) in PBS/35% surfactant (vehicle) ± ESAT-6 peptide 14 (NNALQNLARTISEAG) (20 μg) were delivered to wild-type C57Bl/6 mice. Sham controls received vehicle alone; additional controls received only ESAT-6. Animals were sacrificed at 60 days post instillation for evaluation of lung tissue histopathology, laser capture microdissection (LCM) of granulomas, and bronchoalveolar lavage (BAL) cells as previously described [22].

Characterization of bronchoalveolar lavage (bal) cells

Leukocyte differential counts of BAL cells were calculated from cytospins (100 cells/40 × high power field × 3 fields) as previously described [21]. Aliquots of BAL cells were centrifuged and frozen for qPCR evaluation as previously described [23]. Total RNA was extracted from BAL cells by RNeasy protocol (Qiagen, Valencia, CA). Expression of mRNA was determined by real time qPCR using the ABI Prism 7300 Detection System (TaqMan; Applied Biosystems, Foster City, CA.). Primer-probe sets for CCL2 (MCP1), CCL4 (MIP1β), Fibronectin 1 (Fn1), IFN-γ, PPARγ, Matrix Metalloproteinase-12 (MMP12), osteopontin (OPN), CD3e, and the GAPDH housekeeping gene were obtained from Qiagen, Germantown, MD. Data were expressed as fold change in mRNA expression compared to control values as previously described [21]. Levels of OPN protein in BAL fluid were determined by ELISA assay (R&D Systems, Inc., Minneapolis, MN).

Histological analysis

Lungs were dissected and fixed in PBS 10% formalin. A semiquantitative scoring system previously described [22] was used for a relative comparison of the numbers and quality of the granulomas formed in MWCNT versus ESAT-6 + MWCNT instilled mice. Hematoxylin and Eosin stained sections of lung from each of the experimental mice was assigned a score of between 0 and 5 by two independent investigators using the following scoring system: (score 0) – no granulomas or aggregates of macrophages seen; (score 1) - few small groups of macrophages but no well-formed granulomas; (score 2) - scattered small granulomas not easily seen on scanning power (20X); (score 3) - scattered small granulomas easily seen on scanning power (20X); (score 4) - scattered small granulomas with occasional larger granulomas seen on scanning power (20X); (score 5) - numerous large granulomas easily seen on scanning power. The scores obtained by the two investigators were averaged for the final analysis.


Frozen lung tissue sections (7 μM) were fixed with 4% paraformaldehyde–PBS, permeabilized with Triton X-100, and stained with anti-CD3 antibody (Abcam, Cambridge, MA) at 1:100 dilution, followed by Alexa conjugated goat anti rabbit IgG (Invitrogen, Carlsbad, CA). Slides were counter stained with DAPI (Vector Laboratories, Burlingame, CA) to facilitate nuclear localization. Formalin fixed, paraffin embedded lung tissue sections were stained for Masson’s Trichrome stain (Provia Diagnostics, Greenville, NC)

Statistical analyses

Data were analyzed by student’s t test or one-way analysis of variance (ANOVA) and Tukey’s test using Prism software (GraphPad, Inc., San Diego, CA.).


ESAT-6 exacerbates granulomatous changes

No granulomas were detected in animals receiving sham treatment (Figure 1A) or ESAT-6 alone (Figure 1B). Compared to animals receiving MWCNT alone (Figure 1C), granulomatous changes were more extensive in mice receiving MWCNT + ESAT-6 (Figure 1D). Evaluation of granulomas by a semi-quantitative scoring scale indicated significantly increased (p ≤ 0.05) foci in mice receiving MWCNT + ESAT-6 compared to mice receiving MWCNT alone (Figure 1E).


Figure 1: ESAT-6 exacerbates granulomatous changes. Figures show representative sections of lung from each treatment or control group (Hematoxylin and Eosin, 200x) (n=3/group). No granulomas were detected in either Sham-treated controls (A) or mice treated with ESAT-6 alone (B). Granulomas are visible in mice instilled with MWCNT (C) and are more frequent in mice instilled with the combination of MWCNT + ESAT-6 (D). Analysis by a semi-quantitative scoring system indicated significant (p ≤ 0.05) elevation of granulomatous changes in mice receiving MWCNT + ESAT-6 compared to those receiving MWCNT alone (E).

ESAT-6 elicits fibrosis

Our previous MWCNT studies utilized trichrome staining but detected no fibrosis after instillation of MWCNT alone [10]. Trichrome staining in the current study revealed marked fibrotic changes within granulomas of mice receiving MWCNT + ESAT 6 (Figure 2D) as compared to granulomas of mice receiving only MWCNT (Figure 2C). No fibrosis was detectable in mice receiving sham treatment (Figure 2A) or ESAT-6 alone (Figure 2B). To examine fibrotic changes further, fibronectin 1 (Fn1) mRNA expression was evaluated in LCM sections of lung tissue (Figure 2E). Fn1 was significantly (p ≤ 0.05) elevated in granuloma-positive tissue from MWCNT + ESAT-6 instilled lung compared to granuloma-negative within the same lung. However, granuloma-positive tissue from MWCNT-instilled lung was not different from granuloma-negative (Figure 2E).


Figure 2: ESAT-6 increases fibrosis. Figures show representative sections of lung from each treatment or control group (Trichrome, 200x) (n=3/group). No fibrotic changes were present in either sham-treated controls (A) or mice receiving ESAT-6 alone (B). Mice instilled with MWCNT alone exhibited little fibrosis in granuloma and non-granuloma areas (C). The combination of MWCNT + ESAT-6, however elicited marked fibrosis: the trichrome stain highlights the presence of collagen fibers (stained blue) associated with granulomas (D). qPCR analysis of lung tissues obtained by LCM revealed significant (p ≤ 0.05) elevation of fibronectin (Fn1) in granuloma (+) tissue from mice instilled with MWCNT + ESAT-6 compared to granuloma (-) tissue (E).

ESAT-6 increases CD3 (+) cells within lung tissue but not BAL

Because lymphocyte reactivity to ESAT-6 has been reported in human granulomatous disease (tuberculosis and sarcoidosis) [24], we evaluated lymphocyte distribution and reactivity in mice exposed to ESAT-6 combined with MWCNT. Examination of BAL cell differential counts indicated no significant changes related to ESAT-6 instillation either alone or in combination with MWCNT compared to sham-treated mice (all groups had > 95% alveolar macrophages). As reported in previous MWCNT studies, BAL lymphocyte counts were not significantly altered by MWCNT instillation compared to sham controls [21]. By immunohistochemistry, no CD3 (+) T lymphocytes were detected in lungs of mice receiving vehicle (data not shown) or ESAT-6 alone (Figures 3A and 3B) but CD3 (+) cells were visualized on the periphery of MWCNT-containing granulomatous structures within lung tissues of mice instilled with MWCNT as previously described [21] (Figures 3C and 3D). Compared to MWCNT alone, CD3 (+) cells were more prevalent around granulomas in lung tissues from mice instilled with MWCNT + ESAT-6 (Figures 3E and 3F). To further examine CD3 expression, qPCR was used to quantitate CD3e mRNA within LCM sections of lung tissue (Figure 3G). CD3e was significantly (p ≤ 0.05) elevated in non-granulomatous tissues compared to granulomatous tissues in either MWCNT or MWCNT+ESAT-6 instilled mice. The highest levels of CD3e, however were noted in mice receiving MWCNT+ESAT-6 versus mice receiving only MWCNT (p ≤ 0.05) (Figure 3G).


Figure 3: CD3 (+) lymphocytes are elevated in MWCNT+ESAT-6 lung tissue. Figures show representative areas from bright field and corresponding dark field views of fluorescently stained (anti-CD3 plus Alexa-conjugated second antibody followed by counterstain with DAPI) lung sections from mice instilled with: ESAT-6 alone (A, B); MWCNT (C, D) and MWCNT + ESAT-6 (E, F) (n=3/group). No MWCNT or CD3+ cells are visible in lung sections from mice receiving ESAT-6 alone (A, B). In lung sections from animals instilled with MWCNT alone, CD3 (+) cells are visible in dark field (C) and MWCNT can be seen in bright field (D). Similarly, lung sections from mice receiving MWCNT + ESAT-6 show MWCNT in bright field (F) with increased numbers of CD3 (+) cells in dark field (E) compared to MWCNT alone (C). (G). Expression of CD3e mRNA by qPCR shows significant elevation (p ≤ 0.05) in granuloma (-) versus granuloma (+) tissues. The highest CD3e elevation can be seen in MWCNT+ESAT-6 granuloma (-) tissue compared to granuloma (-) tissue from MWCNT alone (p ≤ 0.05).

Increase of inflammatory mediators in BAL by ESAT-6

Because our previous studies had indicated elevated production of chemokines and other inflammatory mediators in BAL cells in response to MWCNT instillation [21], the effects of ESAT-6 on such mediators were examined. Results indicated that addition of ESAT-6 to MWCNT resulted in a marked increase in BAL production of OPN, a key factor in granuloma formation [25] (Figure 4A). BAL cell OPN mRNA expression in mice instilled with MWCNT + ESAT-6 was significantly (p ≤ 0.05) higher (7.1-fold) than that of MWCNT alone (3.5-fold) (Figure 4A). OPN in ESAT-6 alone did not differ from that of sham controls (Figure 4A). Examination of OPN protein in BAL fluid confirmed this pattern: levels in MWCNT+ ESAT-6 were significantly higher than levels with MWCNT alone (Figure 4B). OPN in mice receiving only ESAT-6 was not different from that of sham controls (Figure 4B).


Figure 4: BAL cell expression of inflammatory mediators is increased by ESAT-6. OPN mRNA expression in response to MWCNT was significantly (p ≤ 0.05) doubled by addition of ESAT-6. OPN expression in response to ESAT-6 alone did not differ from sham controls (A). Similarly OPN protein in BAL fluid was significantly (p<0.05) elevated in MWCNT + ESAT-6 compared to MWCNT alone. OPN in ESAT-6 alone was comparable to sham controls (B). BAL cell mRNA expression of the chemokine, CCL2 was elevated (p<0.05) in mice instilled with MWCNT + ESAT-6 compared to mice receiving only MWCNT. There was no difference in CCL2 expression between sham controls and mice receiving only ESAT-6 (C). BAL cell mRNA expression of MMP12 was significantly (p ≤ 0.05) increased in mice instilled with MWCNT + ESAT-6 compared to mice receiving only MWCNT. MMP-12 expression in ESAT-6 alone did not differ from that of sham control (D).

Similarly, expression levels of the chemokine, CCL2, were also dramatically and significantly (p<0.05) elevated (34.3-fold) by the combination of MWCNT + ESAT-6 compared to MWCNT alone (4-fold) (Figure 4C). BAL cell CCL2 mRNA levels with ESAT-6 alone did not differ from those of sham controls (Figure 4C). Examination of BAL cell MMP-12 mRNA expression also revealed a significant (p ≤ 0.05) increase (27.9-fold) in levels from MWCNT+ESAT-6 instilled mice compared to levels in MWCNT instillation alone (11.3-fold) (Figure 4D). MMP-12 levels in mice receiving ESAT-6 alone did not differ from those of sham controls (Figure 4D).

Decline of interferon-γ expression by ESAT-6

Based upon previous studies showing that ESAT-6 may elicit IFN-γ expression in sensitized animals [26], we evaluated IFN-γ mRNA expression in BAL cells of mice at 60 days after instillation of MWCNT with or without ESAT-6 (Figure 5). Compared to sham controls, BAL cell IFN-γ mRNA expression was significantly (p<0.05) elevated in mice receiving either MWCNT alone or MWCNT+ESAT-6. Surprisingly, IFN-γ expression was reduced after MWCNT + ESAT-6 instillation rather than increased as were other BAL cell inflammatory mediators. There was no significant difference between MWCNT (8- fold) and MWCNT + ESAT-6 (5.7 fold) IFN-γ levels. In mice receiving only ESAT-6, IFN-γ expression was not elevated and was comparable to that of sham controls (Figure 5).


Figure 5: BAL cell expression of Interferon-γ expression is not enhanced by ESAT-6. IFN-γ mRNA ascertained by qPCR was comparably and significantly (p ≤ 0.05) elevated in MWCNT and MWCNT + ESAT-6 compared to sham controls. IFN-γ was undetectable in BAL cells from mice receiving ESAT-6 alone.

Increase of PPARγ expression by ESAT-6

Our previous studies noted that MWCNT-mediated granulomatous inflammation was exacerbated in mice with macrophage-specific PPARγ deficiency [22], therefore it was of interest to determine whether ESAT-6 effects were associated with reduced PPARγ expression. Results indicated that addition of ESAT-6 to MWCNT did not further reduce PPARγ mRNA expression in BAL cells (Figure 6). As noted previously [22], PPARγ mRNA expression became significantly (p ≤ 0.05) depressed in BAL cells from mice instilled with MWCNT (26% of sham control level) while addition of ESAT-6 to MWCNT reduced PPARγ expression to only 60% of sham control level (Figure 6). Both values were significantly (p ≤ 0.05) lower than sham control values but were not different from each other. ESAT-6 alone had no effect and was comparable to sham control.


Figure 6: BAL cell expression of PPARγ is not further decreased by ESAT- 6. PPARγ expression was significantly (p ≤ 0.05) lower than that of sham controls in mice receiving MWCNT or MWCNT + ESAT-6. There was not a significant difference, however between MWCNT versus MWCNT + ESAT- 6 groups. There was no difference in PPARγ expression between sham controls and mice receiving only ESAT-6.


Findings indicate that concurrent instillation of ESAT-6 with MWCNT adversely modifies the pathophysiology of pulmonary granulomatous disease by expanding the extent of granulomatous involvement and introducing fibrotic changes. In our previous studies utilizing only MWCNT, a 100 μg dose was selected as a dose most consistently eliciting granulomas as early as 10 days post instillation [21]. Trichrome staining in those studies did not reveal fibrotic changes. Surprisingly, the addition of ESAT-6 to MWCNT generated marked fibrosis as shown by both Masson Trichrome stain and by elevated fibronectin expression within granulomas. Other MWCNT animal studies have reported rapid development of pulmonary fibrosis by 1-7 days post exposure and persistence through 56 days post exposure [27]. Because our focus is to understand mechanisms operating within a chronic MWCNT disease model, we did not run early time points within the current study as in our initial paper [21]. However, our current results warrant future studies to determine whether the fibrotic effects of ESAT-6 can be detected within an acute inflammatory time period (1-10 days) or are more representative of a delayed response.

By both immunohistochemistry and qPCR, CD3-positive lymphocytes appeared to be more concentrated within pulmonary granulomatous tissues following instillation of combined ESAT-6 and MWCNT than following instillation of MWCNT alone. No CD3 positive cells were apparent with ESAT-6 alone. As noted in previous immunohistochemical findings [21], CD3-positive cells occur adjacent to granulomatous structures rather than within the granulomas themselves. Interestingly, our findings are consistent with previous murine studies of ESAT-6 which indicated that higher numbers of T cells were present in lymph nodes and lung after administration of a microparticle-encapsulated ESAT-6 compared to administration of free ESAT-6 alone which resembled results from untreated controls [26]. Such data suggest the possibility that MWCNT in our study may have functioned as carriers for enhancing ESAT-6 presentation within lung tissue and consequently lymphocytic infiltration. In latent M tuberculosis, T lymphocytes are also elevated within granulomatous lung tissue and are ESAT-6 responsive (i.e. produce IFN-γ) [28]. Our studies, however, did not find that IFN-γ responses in mice instilled with MWCNT + ESAT-6 were greater than those with MWCNT alone. Reduced production of IFN-γ may be related to T cell immunophenotype. In sarcoidosis, T cells with a Th-17 immunophenotype are present in BAL fluid but exhibit reduced IFN-γ responses compared to controls [29].

Some of the most striking data in this study stemming from the inclusion of ESAT-6 with MWCNT were the markedly increased levels of OPN, CCL2, and MMP-12 in BAL cells compared to MWCNT instillation alone. The multifunctional cytokine, OPN, is associated with extracellular matrix signaling and has been cited as necessary for both granuloma formation and fibrosis [30,31]. MMP-12, a metalloelastase, plays a role in several pulmonary fibrosis models [32]. The chemokine, CCL2, has also been associated with lung fibrosis models and blockade of CCL2 has been shown to reduce fibrosis [33]. Data show that differential counts of BAL cells were not altered by ESAT-6/MWCNT but it is possible that ESAT-6 elicited phenotypic changes in macrophages which could account for the increased inflammatory mediators. For example, macrophages of the M-2 activation phenotype have been associated with pulmonary fibrosis [33]. Indeed the upregulation of PPARγ and reduction in IFN-γ expression noted in BAL cells after ESAT-6/MWCNT instillation is more in line with an M-2 rather than an M1 macrophage activation phenotype [34,35]. These and the above results suggest that in analyzing mechanisms by which ESAT-6 alters pulmonary disease when combined with MWCNT, future studies must consider possible phenotypic changes induced by the combination in both macrophages and lymphocytes.

In summary, the instillation of mycobacterial ESAT-6 with MWCNT alters the pulmonary landscape by exacerbating granulomatous disease and inducing fibrotic changes. Others have also shown that MWCNTinduced lung disease is exacerbated by the presence of bacterial lipopolysaccharide. A recent report documented the presence of carbon nanotubes in pediatric airways. These nanotubes were similar to those found in the dust and vehicle exhausts collected within the local environment and suggest that exposure to carbon nanotubes may be wide-spread within the population. Such findings combined with the current data suggest that an underlying carbon nanotube presence could adversely affect the outcome of microbial pulmonary disease in susceptible populations [36,37].


This work was supported by NIH grant ES 022462 and North Carolina Biotechnology Center grant BRG12-06.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 24th World Congress on Nanomaterials and Nanotechnology
    July 12-13, 2018 Bangkok, Thailand
  • 2nd World Congress on Nano Science and Nano Technology
    August 10-11, 2018 Osaka, Japan
  • 25th Nano Congress for Future Advancements
    August 16-18, 2018 Dublin, Ireland
  • 20th Asia Pacific Nanotechnology Congress
    July 23-24, 2018 Sydney, Australia
  • 26th International Conference on Advanced Nanotechnology
    October 04-05 2018 Moscow, Russia
  • Nanotechnology & Materials Engineering
    Oct 25-26, 2018 Budapest, Hungary

Article Usage

  • Total views: 8355
  • [From(publication date):
    December-2015 - Jun 18, 2018]
  • Breakdown by view type
  • HTML page views : 8244
  • PDF downloads : 111

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7